GlassScriptPhysician profile
Talha Riaz
NPI 1760898647
$5,209.04
in general payments reported to CMS, 2019-2025
52 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $24.60 · 2021: $93.39 · 2022: $851 · 2023: $1,535 · 2024: $936 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.58 |
| Education | $116.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $747.22 | 2021-2025 | Enhertu |
| Abbvie INC. | $301.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $275.96 | 2022-2025 | |
| Pfizer INC. | $196.67 | 2019-2025 | |
| Puma Biotechnology, INC. | $187.86 | 2022-2023 | Nerlynx |
| Celgene Corporation | $184.57 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Immunocore Limited | $180.60 | 2023-2025 | Kimmtrak |
| Amgen INC. | $170.37 | 2022-2023 | Kyprolis, Vectibix, Nplate |
| E.R. Squibb & Sons, L.L.C. | $167.52 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Sirtex Medical INC | $162.32 | 2023-2024 | Sir-Spheres Microspheres |
| Merck Sharp & Dohme LLC | $158.45 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $155.96 | 2022-2025 | Enhertu, Calquence, Lynparza |
| Stemline Therapeutics INC. | $142.54 | 2023-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $141.38 | 2019-2022 | |
| Novocure INC. | $140.42 | 2025 | Optune Lua (Novottf-200t) |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $116.43 | 2022-2025 | |
| Beigene USA, INC. | $108.45 | 2020-2024 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $105.93 | 2022-2025 | Jemperli, Ojjaara |
| Gilead Sciences, INC. | $103.71 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $95.63 | 2022-2025 | Fruzaqla, Ninlaro |
| Genentech USA, INC. | $91.70 | 2019-2023 | Tecentriq |
| Lilly USA, LLC | $86.53 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Adc Therapeutics America, INC. | $85.19 | 2022-2025 | |
| Genzyme Corporation | $83.62 | 2023-2025 | |
| Incyte Corporation | $77.19 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Pharmaessentia USA Corporation | $61.52 | 2023-2025 | Besremi |
| Janssen Biotech, INC. | $61.36 | 2023-2025 | Balversa, Akeega, Erleada |
| Sobi, INC | $59.48 | 2023-2025 | |
| Kite Pharma, INC. | $57.91 | 2023-2025 | Yescarta |
| Astellas Pharma US INC | $56.28 | 2022-2024 | Vyloy |
| Blueprint Medicines Corporation | $51.52 | 2024-2025 | Ayvakit |
| Seagen INC. | $42.98 | 2022-2023 | Adcetris |
| Sun Pharmaceutical Industries INC. | $42.34 | 2022-2023 | Yonsa, Odomzo |
| Regeneron Healthcare Solutions, INC. | $39.08 | 2023-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $38.80 | 2022-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $36.05 | 2022-2025 | |
| Acrotech Biopharma INC. | $34.82 | 2022-2023 | Beleodaq |
| Beone Medicines USA, INC. | $34.44 | 2025 | Tevimbra |
| Epizyme, INC. | $32.48 | 2021 | |
| Mirati Therapeutics, INC. | $29.69 | 2023 | Krazati |
| Tempus Ai, INC | $29.40 | 2024 | |
| Deciphera Pharmaceuticals INC. | $26.44 | 2025 | Romvimza, Qinlock |
| Apellis Pharmaceuticals, INC. | $25.14 | 2024 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $24.44 | 2022 | |
| Genmab U.S., INC. | $21.76 | 2023 | Tivdak |
| Exelixis INC. | $21.54 | 2025 | Cabometyx |
| Cti Biopharma Corp. | $20.49 | 2023 | Vonjo |
| Array Biopharma INC | $20.37 | 2024 | Mektovi, Xalkori, Lorbrena |
| Recordati_rare_diseases_inc. | $19.58 | 2025 | Sylvant |
| Tersera Therapeutics LLC | $18.62 | 2024 | Zoladex |
| Caris Mpi, INC. | $18.43 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.65 | 2024 | Gilotrif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talha Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.